Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for prevention of left ventricular thrombus after anterior STEMI treated with primary PCI
ChiCTR1900026249Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in myocardial infarction (MI) and coronary arteriosclerosis (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Formation of left ventricular thrombus. Started Oct 2019; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900026249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026249.